740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Mansoor Raza Mirza, Sudarshan Sharma, Jørn Herrstedt, Mark S. Shahin, David Cibula, Emily Fleming, Francesco Raspagliesi, Joseph Buscema, Lars Hanker, Robert L. Coleman, Ingrid Boere, Kami Wolfe Schneider, Lucy Gilbert, Brian M. Slomovitz, Michael Teneriello, Matthew A. Powell, Suman Ghosh, S. Stevens, Kari L. Ring, Ashley Stuckey